

## AMENDMENTS TO THE CLAIMS

Amend the claims as follows:

1. (Currently amended): An isolated polypeptide comprising an amino acid sequence selected from the group consisting of:

- Sub c1*  
*B3*
- a) ~~amino acid sequence of~~ SEQ ID NO:4;
  - b) ~~a mature form of amino acid sequence~~ SEQ ID NO:4;
  - c) ~~a variant of a mature form of an amino acid sequence of~~ SEQ ID NO:4; and
  - d) ~~a fragment of the amino acid sequence described in a) to c)~~, wherein said polypeptide has growth factor activity.

2. (Currently amended): The polypeptide of claim 1, wherein said polypeptide is a FCTR2 fragment of a FCTR~~X~~ polypeptide selected from the group consisting of amino acid residues 247-370 of SEQ ID NO:2, amino acid residues 247-338 of SEQ ID NO:2, and amino acid residues 339-370 of SEQ ID NO:2.

3. – 39. (Cancelled)

40. (Original): A pharmaceutical composition comprising a polypeptide of claim 1 and a pharmaceutically acceptable carrier.

41. – 65. (Cancelled)

*Sub c1*  
*B*

66. (New): A polypeptide dimer comprising two associated peptide fragments, wherein said peptide fragments are selected from the group consisting of amino acid residues 247-370 of SEQ ID NO:2, amino acid residues 247-338 of SEQ ID NO:2, and amino acid residues 339-370 of SEQ ID NO:2.